An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT07709533 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

347

Enrollment

OTHER

Sponsor class

Conditions

Valid MeSH Conditions

Interventions

DRUG: Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor
DRUG: Retlirafusp alfa / Indole-3-carbinol + Black garlic fermentation extract / Lactobacillus rhamnosus / Placebo + Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor

Sponsor

Sun Yat-sen University